

eXegenics Inc  
Form 4  
March 29, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Eichler David A

(Last) (First) (Middle)  
625 AVENUE OF THE AMERICAS  
  
(Street)

NEW YORK, NY 10011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
eXegenics Inc [EXEG]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/27/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Code V Amount (D) Price   |  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Underlying Security (Instr. 3 and 4) |
|--|------------------------------------|--------------------------------------|--|--------------------------------|--|--|---|
|  |                                    |                                      |  |                                |  |  |   |

Edgar Filing: eXegenics Inc - Form 4

|                                      | Derivative Security |            | Disposed of (D)<br>(Instr. 3, 4, and 5) |           | Date Exercisable | Expiration Date | Title        |
|--------------------------------------|---------------------|------------|---|-----------|------------------|-----------------|--------------|
|                                      |                     |            | Code                                    | V (A) (D) |                  |                 |              |
| Series C Convertible Preferred Stock | \$ 0                | 03/27/2007 | J <sup>(1)</sup>                        | 90,815    | <u>(2)</u>       | <u>(2)</u>      | Common Stock |
| Warrant (Right to Buy)               | \$ 0.002            | 03/27/2007 | J <sup>(1)</sup>                        | 1,135,188 | <u>(4)</u>       | 03/27/2017      | Common Stock |
| Warrant(Right to Buy)                | \$ 0.6728           | 03/27/2007 | J <sup>(1)</sup>                        | 309,737   | <u>(4)</u>       | 03/27/2017      | Common Stock |
| Warrant (Right to Buy)               | \$ 0.8473           | 03/27/2007 | J <sup>(1)</sup>                        | 309,737   | <u>(4)</u>       | 03/27/2017      | Common Stock |
| Warrant (Right to Buy)               | \$ 1.0466           | 03/27/2007 | J <sup>(1)</sup>                        | 309,737   | <u>(4)</u>       | 03/27/2017      | Common Stock |
| Stock Option (Right to Buy)          | \$ 0.04             | 03/27/2007 | J <sup>(1)</sup>                        | 25,947    | <u>(5)</u>       | 11/08/2014      | Common Stock |
| Stock Option (Right to Buy)          | \$ 0.04             | 03/27/2007 | J <sup>(1)</sup>                        | 103,788   | <u>(5)</u>       | 02/15/2015      | Common Stock |
| Stock Option (Right to Buy)          | \$ 0.05             | 03/27/2007 | J <sup>(1)</sup>                        | 155,682   | <u>(6)</u>       | 02/28/2016      | Common Stock |

## Reporting Owners

| Reporting Owner Name / Address                                      | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Eichler David A<br>625 AVENUE OF THE AMERICAS<br>NEW YORK, NY 10011 |               | X         |         |       |

## Signatures

/s/ David A. Eichler  
03/29/2007

\*\*Signature of Reporting Person  
Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
- (2) These shares are currently exercisable and do not expire.
- (3) As Managing Director of Psilos Group Investors II-S, LLC, the General Partner of Psilos Group Partners II SBIC, L.P.
- (4) These warrants are currently exercisable.
- (5) These options are fully vested.
- (6) 56,218.83 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.